PMID- 12903007
OWN - NLM
STAT- MEDLINE
DCOM- 20040212
LR  - 20220410
IS  - 1053-4296 (Print)
IS  - 1053-4296 (Linking)
VI  - 13
IP  - 3
DP  - 2003 Jul
TI  - CTCAE v3.0: development of a comprehensive grading system for the adverse effects 
      of cancer treatment.
PG  - 176-81
AB  - Multiple systems have been developed for grading the adverse effects (AEs) of 
      cancer treatment. The National Cancer Institute Common Toxicity Criteria (CTC) 
      system has substantially evolved since its inception in 1983. The most recent 
      version, CTCAE v3.0 (Common Terminology Criteria for Adverse Events version 3.0) 
      represents the first comprehensive, multimodality grading system for reporting 
      the acute and late effects of cancer treatment. The new CTC requires changes in 
      the application of AE criteria including new guidelines regarding late effects, 
      surgical and pediatric effects, multimodality issues, and for reporting the 
      duration of an effect. It builds on the strengths of previous systems, represents 
      a considerable effort among hundreds of participants, and signifies an 
      international collaboration and consensus of the oncology research community. 
      This article updates recent progress in the evolution of adverse effects grading 
      systems and reviews the development of CTCAE v3.0.
FAU - Trotti, Andy
AU  - Trotti A
AD  - H. Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL 33612, 
      USA. Trotti@moffitt.usf.edu
FAU - Colevas, A Dimitrios
AU  - Colevas AD
FAU - Setser, Ann
AU  - Setser A
FAU - Rusch, Valerie
AU  - Rusch V
FAU - Jaques, David
AU  - Jaques D
FAU - Budach, Volker
AU  - Budach V
FAU - Langer, Corey
AU  - Langer C
FAU - Murphy, Barbara
AU  - Murphy B
FAU - Cumberlin, Richard
AU  - Cumberlin R
FAU - Coleman, C Norman
AU  - Coleman CN
FAU - Rubin, Philip
AU  - Rubin P
LA  - eng
GR  - R13 CA 93030-01/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Semin Radiat Oncol
JT  - Seminars in radiation oncology
JID - 9202882
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Academies and Institutes
MH  - Antineoplastic Agents/*adverse effects
MH  - Humans
MH  - Information Services/*organization & administration
MH  - Neoplasms/*therapy
MH  - Radiotherapy/*adverse effects
MH  - Surgical Procedures, Operative/*adverse effects
MH  - *Terminology as Topic
RF  - 11
EDAT- 2003/08/07 05:00
MHDA- 2004/02/13 05:00
CRDT- 2003/08/07 05:00
PHST- 2003/08/07 05:00 [pubmed]
PHST- 2004/02/13 05:00 [medline]
PHST- 2003/08/07 05:00 [entrez]
AID - S1053-4296(03)00031-6 [pii]
AID - 10.1016/S1053-4296(03)00031-6 [doi]
PST - ppublish
SO  - Semin Radiat Oncol. 2003 Jul;13(3):176-81. doi: 10.1016/S1053-4296(03)00031-6.